World's Best Scientists 2026 revealed!

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Immunology 97 810 740 455 409 383 40479
Medicine 97 9172 8613 4731 4378 393 40484

Ann C. Collier publications per year

The chart shows the history of publications by Ann C. Collier between 1984 and 2025, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Ann C. Collier published across 42 years, from 1984 to 2025, averaging 9.5 papers a year. Output peaked at 29 publications in 2011. 11 of the 401 publications appeared in the last two years.

No. of publications
5 10 15 20 25
Bar chart. Horizontal axis: year, 1984 to 2025. Vertical axis: number of publications, 0 to 29. Peak 29 publications in 2011. 1984: 4 publications 1985: 3 publications 1986: 1 publication 1987: 5 publications 1988: 5 publications 1989: 2 publications 1990: 10 publications 1991: 7 publications 1992: 4 publications 1993: 6 publications 1994: 6 publications 1995: 12 publications 1996: 10 publications 1997: 7 publications 1998: 10 publications 1999: 11 publications 2000: 11 publications 2001: 17 publications 2002: 8 publications 2003: 3 publications 2004: 6 publications 2005: 7 publications 2006: 7 publications 2007: 8 publications 2008: 8 publications 2009: 11 publications 2010: 13 publications 2011: 29 publications 2012: 19 publications 2013: 22 publications 2014: 14 publications 2015: 14 publications 2016: 10 publications 2017: 12 publications 2018: 11 publications 2019: 16 publications 2020: 14 publications 2021: 14 publications 2022: 6 publications 2023: 7 publications 2024: 4 publications 2025: 7 publications
1984 2025

401 publications in total across all disciplines

View publications per year as a table
Ann C. Collier: publications per year, 1984 to 2025
Year Publications
1984 4
1985 3
1986 1
1987 5
1988 5
1989 2
1990 10
1991 7
1992 4
1993 6
1994 6
1995 12
1996 10
1997 7
1998 10
1999 11
2000 11
2001 17
2002 8
2003 3
2004 6
2005 7
2006 7
2007 8
2008 8
2009 11
2010 13
2011 29
2012 19
2013 22
2014 14
2015 14
2016 10
2017 12
2018 11
2019 16
2020 14
2021 14
2022 6
2023 7
2024 4
2025 7
Total 401
Download as CSV

Ann C. Collier publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Ann C. Collier sits on this spectrum.

No. of scientists
50 100 150
Bar chart with 76 bars. Horizontal axis: publications, 62–71 to 807+. Vertical axis: number of scientists, 0 to 189. Most scientists, 189, have 152–161 publications. The last bar groups every scientist with 807 publications or more. The highlighted bar, 382–391 publications, is where this scientist sits. 62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 69 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientist 807+ publications: 100 scientists
62–71 publications 807+

This scientist: 383 publications — 79th percentile

79% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

View publications distribution as a table
Number of Immunology scientists by publication count, Research.com 2026 ranking edition. Based on 4,929 ranked scientists.
Publications Scientists This scientist
62–71 9
72–81 23
82–91 40
92–101 72
102–111 86
112–121 108
122–131 150
132–141 160
142–151 159
152–161 189
162–171 166
172–181 181
182–191 188
192–201 187
202–211 178
212–221 158
222–231 168
232–241 159
242–251 160
252–261 148
262–271 116
272–281 125
282–291 115
292–301 111
302–311 95
312–321 97
322–331 97
332–341 99
342–351 96
352–361 69
362–371 76
372–381 71
382–391 71 383
392–401 62
402–411 54
412–421 41
422–431 63
432–441 53
442–451 31
452–461 42
462–471 40
472–481 29
482–491 34
492–501 30
502–511 23
512–521 41
522–531 29
532–541 28
542–551 16
552–561 18
562–571 18
572–581 17
582–591 17
592–601 17
602–611 19
612–621 13
622–631 12
632–641 11
642–651 16
652–661 9
662–671 5
672–681 13
682–691 12
692–701 6
702–711 6
712–721 9
722–731 9
732–741 6
742–751 11
752–761 10
762–771 7
772–781 12
782–791 7
792–801 5
802–806 1
807+ 100
Download as CSV

Ann C. Collier D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Ann C. Collier sits on this spectrum.

No. of scientists
50 100 150 200
Bar chart with 60 bars. Horizontal axis: D-Index, 40–41 to 157+. Vertical axis: number of scientists, 0 to 201. Most scientists, 201, have 58–59 D-Index. The last bar groups every scientist with 157 D-Index or more. The highlighted bar, 96–97 D-Index, is where this scientist sits. 40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 163 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40–41 D-Index 157+

This scientist: 97 D-Index — 84th percentile

84% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

View D-Index distribution as a table
Number of Immunology scientists by D-index, Research.com 2026 ranking edition. Based on 4,929 ranked scientists.
D-Index Scientists This scientist
40–41 28
42–43 91
44–45 157
46–47 192
48–49 175
50–51 188
52–53 177
54–55 155
56–57 194
58–59 201
60–61 197
62–63 201
64–65 173
66–67 167
68–69 172
70–71 199
72–73 184
74–75 133
76–77 163
78–79 127
80–81 121
82–83 125
84–85 121
86–87 102
88–89 96
90–91 75
92–93 72
94–95 74
96–97 66 97
98–99 68
100–101 49
102–103 60
104–105 54
106–107 36
108–109 23
110–111 52
112–113 41
114–115 34
116–117 25
118–119 28
120–121 11
122–123 20
124–125 27
126–127 19
128–129 20
130–131 16
132–133 17
134–135 14
136–137 15
138–139 9
140–141 11
142–143 9
144–145 9
146–147 7
148–149 7
150–151 7
152–153 5
154–155 8
156 6
157+ 96
Download as CSV

Overview

Ann C. Collier is affiliated with the University of Washington in the United States. Their research primarily centers on breast cancer, with a focus on advanced breast cancer therapies and cancer treatment pharmacology. The scope of their work also includes investigations into HER2/EGFR in cancer research, estrogen and related hormone effects, cancer genomics and diagnostics, breast cancer treatment studies, and BRCA gene mutations in cancer.

Their publication record includes studies published across several prominent venues:

  • Annals of Oncology
  • Journal of Clinical Oncology
  • Cancer Research
  • npj Breast Cancer
  • Clinical Cancer Research

Main fields of study include Medicine and Biochemistry, Genetics and Molecular Biology, highlighting a multidisciplinary approach to cancer research. Subfields addressed in their work encompass Pulmonary and Respiratory Medicine, Oncology, Cancer Research, and Genetics.

Recent papers authored or coauthored by Ann C. Collier are:

  • "CDK4/6i-treated HR+/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscape," 2024, npj Breast Cancer
  • "Interim analyses (IA) of the giredestrant (G), G + abemaciclib (A), and G + ribociclib (R) arms in MORPHEUS Breast Cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced/metastatic BC (ER+, HER2- LA/mBC)," 2023, Journal of Clinical Oncology
  • "An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer," 2023, Clinical Cancer Research
  • "365P Interim analysis (IA) of the giredestrant (G) + samuraciclib (SAMURA) arm in MORPHEUS breast cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with oestrogen receptor-positive (ER+), HER2-negative, locally advanced/metastatic BC (LA/mBC)," 2024, Annals of Oncology
  • "395P Interim analysis (IA) of the giredestrant (G) + ipatasertib (IPAT) arm in MORPHEUS Breast Cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with oestrogen receptor-positive (ER+), HER2-negative, locally advanced/metastatic BC (LA/mBC)," 2023, Annals of Oncology

Frequent coauthors contributing to these studies include:

  • Heather M. Moore
  • Joohyuk Sohn
  • Jorge Martinalbo
  • Mafalda Oliveira
  • Kyung Hae Jung

Best Publications

  • HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study.

    R. K. Heaton;D. B. Clifford;D. R. Franklin;S. P. Woods

  • HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors

    Robert K. Heaton;Donald R. Franklin;Ronald J. Ellis;J. Allen McCutchan

  • Effect of early versus deferred antiretroviral therapy for HIV on survival.

    Mari M. Kitahata;Stephen J. Gange;Alison G. Abraham;Barry Merriman

  • Antiretroviral-Drug Resistance among Patients Recently Infected with HIV

    Susan J. Little;Sarah Holte;Jean Pierre Routy;Eric S. Daar

  • Clinical and epidemiologic features of primary HIV infection.

    Timothy W Schacker;Ann C. Collier;James Hughes;Theresa Shea

  • Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.

    Ann C. Collier;Robert W. Coombs;David A. Schoenfeld;Roland L. Bassett

  • Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system.

    Scott Letendre;Jennifer Marquie-Beck;Edmund Capparelli;Brookie Best

  • Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease.

    Edward L. Murphy;Ann C. Collier;Leslie A. Kalish;Susan F. Assmann

  • The prevalence and incidence of neurocognitive impairment in the HAART era.

    Kevin R. Robertson;Marlene Smurzynski;Thomas D. Parsons;Kunling Wu

  • Plasma Viremia in Human Immunodeficiency Virus Infection

    Robert W. Coombs;Ann C. Collier;Jean-P. Allain;Beverly Nikora

  • Invasion of the central nervous system by Treponema pallidum: implications for diagnosis and treatment.

    Sheila A. Lukehart;Edward W. Hook;Sharon A. Baker-Zander;Ann C. Collier

  • CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy.

    Ronald J. Ellis;Jayraan Badiee;Florin Vaida;Scott Letendre

  • Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein

    E. L. Cooney;E. L. Cooney;E. L. Cooney;A. C. Collier;A. C. Collier;A. C. Collier;P. D. Greenberg;P. D. Greenberg;P. D. Greenberg;R. W. Coombs;R. W. Coombs;R. W. Coombs

  • Prevalence and predictive value of intermittent viremia with combination hiv therapy.

    Diane V. Havlir;Roland Bassett;Diane Levitan;Peter Gilbert

  • Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection

    Craig W. Hendrix;Ann C. Collier;Michael Marcel Lederman;Dominique Schols

  • Neurocognitive Change in the Era of HIV Combination Antiretroviral Therapy: The Longitudinal CHARTER Study

    Robert K. Heaton;Donald R. Franklin;Reena Deutsch;Scott Letendre

  • Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.

    Paul E. Sax;Camlin Tierney;Ann C. Collier;Margaret A. Fischl

  • Neurologic relapse after benzathine penicillin therapy for secondary syphilis in a patient with HIV infection.

    Carol Dawn Berry;Thomas M. Hooton;Ann C. Collier;Sheila A. Lukehart

  • A Randomized Controlled Trial of a Reduced Daily Dose of Zidovudine in Patients with the Acquired Immunodeficiency Syndrome

    Margaret A. Fischl;Corette B. Parker;Carla Pettinelli;Michael Wulfsohn

  • Continued High Prevalence and Adverse Clinical Impact of Human Immunodeficiency Virus–Associated Sensory Neuropathy in the Era of Combination Antiretroviral Therapy: The CHARTER Study

    Ronald J. Ellis;Debralee Rosario;David B. Clifford;Justin C. McArthur

  • Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1

    Eric S. Daar;Camlin Tierney;Margaret A. Fischl;Paul E. Sax

  • Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens.

    Diane V. Havlir;Nick S. Hellmann;Christos J. Petropoulos;Jeannette M. Whitcomb

Frequent Co-Authors

David B. Clifford
David B. Clifford Washington University in St. Louis
Igor Grant
Igor Grant University of California, San Diego
Benjamin B. Gelman
Benjamin B. Gelman The University of Texas Medical Branch at Galveston
Ronald J. Ellis
Ronald J. Ellis University of California, San Diego
Susan Morgello
Susan Morgello Icahn School of Medicine at Mount Sinai
Justin C. McArthur
Justin C. McArthur Johns Hopkins University School of Medicine
Robert W. Coombs
Robert W. Coombs University of Washington
Scott Letendre
Scott Letendre University of California, San Diego
Robert K. Heaton
Robert K. Heaton University of California, San Diego
J. Allen McCutchan
J. Allen McCutchan University of California, San Diego

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in merging immunology knowledge with advanced healthcare roles, pursuing a Nurse Practitioner degree can be a strategic path. Many students explore the easiest np program options to balance rigorous study with personal commitments, ensuring a smooth transition into the nursing field.

Specializations such as Psychiatric Mental Health Nurse Practitioner (PMHNP) programs offer focused clinical training and growing career opportunities. When researching the best fit, candidates often consider the top pmhnp programs known for their excellent clinical placement rates to gain practical experience crucial for success.

Cost is another important factor. Students frequently seek out the cheapest pmhnp programs to pursue quality education without overwhelming financial burden. Evaluating tuition and financial aid options can make advanced degrees more accessible.

Finally, understanding career outcomes is essential before commitment. Resources detailing dnp salary transparency provide valuable insights on earning potential across states, helping students align their education with long-term professional goals.

Best Scientists Citing Ann C. Collier

Trending Scientists

Recently Published Articles